Retraction Note to: Chronic NMDA administration to rats increases brain pro-apoptotic factors while decreasing anti-Apoptotic factors and causes cell death

Abstract Background Chronic N -Methyl-D-aspartate (NMDA) administration to rats is reported to increase arachidonic acid signaling and upregulate neuroinflammatory markers in rat brain. These changes may damage brain cells. In this study, we determined if chronic NMDA administration (25 mg/kg i.p., 21 days) to rats would alter expression of pro- and anti-apoptotic factors in frontal cortex, compared with vehicle control. Results Using real time RT-PCR and Western blotting, chronic NMDA administration was shown to decrease mRNA and protein levels of anti-apoptotic markers Bcl-2 and BDNF, and of their transcription factor phospho-CREB in the cortex. Expression of pro-apoptotic Bax, Bad, and 14-3-3ζ was increased, as well as Fluoro-Jade B (FJB) staining, a marker of neuronal loss. Conclusion This alteration in the balance between pro- and anti-apoptotic factors by chronic NMDA receptor activation in this animal model may contribute to neuronal loss, and further suggests that the model can be used to examine multiple processes involved in excitotoxicity.

We have established an animal model of excessive NMDA signaling in rats by administering a subconvulsive dose of NMDA for 21 days. This model demonstrates upregulated markers of brain AA metabolism, including increased turnover of AA in brain phospholipids and increased expression of AA-selective cPLA 2 and the cPLA 2 gene transcription factor, activator protein (AP)-2 [6,35]. It also demonstrates increased brain neuroinflammatory markers, consistent with crosstalk between NMDAR-mediated excitotoxicity and neuroinflammation [4].
In our present study, we wished to see if chronic NMDA administration to rats, as a model of excitotoxicity, also would alter the balance of pro-and anti-apoptotic factors in brain and lead to neuronal death. To the extent that this model represents clinical excitotoxicity, it might be used for drug development and for understanding interactions among different brain processes that lead to cell death. We studied the frontal cortex because we had studied this region previously in this model [4,6].

Animals
The study was conducted following the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals (Publication no. 80-23) and was approved by the Animal Care and Use Committee of the "Eunice Kennedy Shriver" National Institute of Child Health and Human Development. Male CDF-344 rats weighing 200-215 g (Charles River Laboratories; Wilmington, MA, USA) were randomly assigned to a control group (n = 10) that received vehicle (0.9% saline i.p.) once daily for 21 days, or to an NMDA group (n = 10) that received 25 mg/kg i.p. NMDA (Sigma Chemical Co., St Louis, MO, USA) once daily for 21 days. This dose does not produce convulsions but can cause paroxysmal EEG activity [36] and an increase in brain AA metabolism in rats [37]. Three hours after the last saline or NMDA injection, rats were anesthetized with CO 2 and then decapitated. The brain was rapidly excised and the frontal cortex dissected, frozen in 2methylbutane at -50°C, and stored at -80°C until use.

Preparation of Cytosolic Fractions
Cytosolic fractions were prepared from frontal cortex as previously described [6]. Tissue from control or chronic NMDA rats was homogenized with a Polytron homogenizer in a buffer consisting of 20 mM Tris-HCl (pH 7.4), 2 mM EGTA, 5 mM EDTA, 1.5 mM pepstatin, 2 mM leupeptin, 0.5 mM phenylmethylsulfonyl fluoride, 0.2 U/ml aprotinin, and 2 mM dithiothreitol. The suspension was centrifuged at 100,000 × g for 60 min at 4°C. The resulting supernatant was the cytosolic fraction. Protein concentrations of cytosolic fractions were determined by using a protein reagent (Bio-Rad, Hercules, CA).
The frontal cortex nuclear fraction was prepared from the control and NMDA administered rats as previously described [6].

BDNF and phospho-CREB Protein Levels
BDNF and phospho-cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) levels were measured in brain cytosolic and nuclear extracts using an ELISA kit according to the manufacturer's instructions (Chemicon International, Temecula, CA). BDNF levels are expressed in pmol/mg protein and phospho-CREB levels were expressed as percent of control.

Total RNA Isolation and RT-PCR
Total RNA was isolated from frontal cortex of control and chronic NMDA-administered rats using an RNeasy lipid tissue mini kit (Qiagen, Valencia, CA, USA). Expression of BDNF, Bcl-2, Bax, and Bad was determined using specific primers and probes purchased from TaqMan R gene expression assays (Applied Biosystems). Data were expressed as the level of the target gene mRNA in brain from NMDAadministered animals normalized to the level of the endogenous control mRNA (β-globulin), and relative to values in brains from control saline-injected rats (calibrator) [38]. All experiments were carried out in duplicate with six independent samples per group.

FJB staining
Brains from control and NMDA administered rats (frontal cortex) were sectioned coronally (25 μm) on a cryostat (Bright Instrument Company, Ltd., Huntingdon, England) and then mounted on gelatin-coated glass specimen slides. Staining with FJB (Histo-Chem, Jefferson, AR) was performed as described [39]. Briefly, the tissue slides were dehydrated in 70% ethanol and then hydrated with distilled water. After hydration, they were immersed in FJB stain for 20 min at room temperature, washed with distilled water and dried at 50°C for 10 min. The slides were mounted with the cover slip with DPX and examined under a fluorescence microscope.

Statistical Analysis
Data are expressed as means ± SEM. Statistical significance was calculated using two-tailed, unpaired t-test, with significance set at p < 0.05.

Decreased levels of anti-apoptotic factors
Chronic NMDA administration for 21 days, compared with chronic saline, significantly decreased protein levels of BDNF (75%; p < 0.001) ( Figure 1A), Bcl-2 (33%; p < Protein levels of BDNF (A) and Bcl-2 (B) in frontal cortex of control rats (n = 10) and chronic NMDA-treated rats (n = 10), measured using ELISA and immunoblot as described in the method section Figure 1 Protein levels of BDNF (A) and Bcl-2 (B) in frontal cortex of control rats (n = 10) and chronic NMDA-treated rats (n = 10), measured using ELISA and immunoblot as described in the method section. Optical densities of immunoblot bands were normalized to b-actin to correct for unequal loading. Values are expressed as percent of control. Phosphorylated CREB (C) was measured in frontal cortex of control rats (n = 8) and of chronic NMDA-treated rats (n = 8) by ELISA, as described in manufacturer's instructions. mRNA levels of BDNF (C) and Bcl-2 (D) in frontal cortex of control rats (n = 6) and of chronic NMDA-treated rats (n = 6), measured using RT-PCR. Data are expressed as mRNA level in frontal cortex of chronic NMDA administered rats, normalized to the endogenous level of β-globulin mRNA, and relative to the control (calibrator), using the ΔΔC T method (means ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001). 0.05) ( Figure 1B), and phospho-CREB (39%; p < 0.001) ( Figure 1C) in rat frontal cortex. The decreases in these protein levels were associated with decreases in their mRNA levels. Thus, chronic NMDA significantly decreased mRNA levels of BDNF (0.6 fold; p < 0.01) (Figure 1D) and of Bcl-2 (0.6 fold; p < 0.01) ( Figure 1E).

Evidence of cell death
Chronic NMDA administration increased FJB staining, a marker of neuronal loss, in rat frontal cortex ( Figure 3B).

Discussion
Chronic daily administration of a non-convulsive dose of NMDA to adult male rats significantly decreased frontal cortex protein and mRNA levels of the anti-apoptotic factors BDNF and Bcl-2, and of their transcription factor, phospho-CREB. In contrast, chronic NMDA significantly increased frontal cortex protein and mRNA levels of Bad Protein levels of Bad (A) and Bax (B) in frontal cortex of control rats (n = 8) and of chronic NMDA-treated rats (n = 8), meas-ured using immunoblot Figure 2 Protein levels of Bad (A) and Bax (B) in frontal cortex of control rats (n = 8) and of chronic NMDA-treated rats (n = 8), measured using immunoblot. Optical densities of immunoblot bands were normalized to b-actin to correct for unequal loading. Values are expressed as percent of control. Data are expressed as means ± SEM, *p < 0.05, **p < 0.01. mRNA levels of Bad (C) and Bax (D) in frontal cortex of control rats (n = 6) and of chronic NMDA-treated rats (n = 6), measured using RT-PCR. Data are expressed as mRNA level in frontal cortex of chronic NMDA administered rats, normalized to the endogenous level of β-globulin mRNA, and relative to the control (calibrator), using the ΔΔC T method (means ± SEM, *p < 0.05, **p < 0.01).
and Bax and of the protein level of 14-3-3ζ, pro-apoptotic factors, as well as Fluoro Jade-B staining, a marker of neuronal death, in rat frontal cortex. These data can be added to evidence that chronic NMDA under the same administration paradigm increased frontal cortex expression of inflammatory markers (protein and mRNA levels of interleukin-1 beta, tumor necrosis factor alpha, glial fibrillary acidic protein and inducible nitric oxide synthase) [4], decreased frontal cortex NMDAR (NR)-1 and NR-3A subunits, and increased activity, phosphorylation, protein, and mRNA levels of cPLA 2 but did not change activity or protein levels of secretory sPLA 2 or calcium-independent iPLA 2 [6]. Chronic NMDA also increased the DNA-binding activity of AP-2 and its protein levels of AP-2 alpha and beta subunits [6], which are recognized on the promoter region of cPLA 2 gene [40] as well as turnover and other kinetic markers of AA metabolism in frontal cortex of rat brain [35]. These changes did not follow administration of a single 25 mg/kg i.p. dose of NMDA and thus were a consequence of long term activation of NMDARs [6]. Together, they provide a profile of an experimental and probably evolving animal model of excitotoxicity, which might be exploited for future drug development and for understanding interactions of processes of excitotoxicity. There is evidence that excitotoxicity plays a role in a number of neuropsychiatric and neurodegenerative disorders, including Alzheimer disease [9][10][11], Huntington's disease [12], schizophrenia [13], and bipolar disorder [14,16,41].
The effects of chronic NMDA in rats suggest alterations of multiple signaling cascades such as calpain [2], calcineurin [3] and iNOS expression [4] but it may be premature to ascribe a change in one to a change in another. Nevertheless, increased AA metabolism caused by chronic NMDA may be involved in altering the balance between pro-and anti-apoptotic factors, leading in turn to the observed neuronal loss. Increased AA exposure decreased A Protein levels of 14-3-3-ζ in frontal cortex of control rats (n = 6) and of chronic NMDA-treated rats (n = 6), measured using immunoblotting Figure 3 A Protein levels of 14-3-3-ζ in frontal cortex of control rats (n = 6) and of chronic NMDA-treated rats (n = 6), measured using immunoblotting. Optical densities of immunoblot bands were normalized to b-actin to correct for unequal loading. Values are expressed as percent of control. Data are expressed as means ± SEM, *p < 0.05. B. Representative FJB stained frontal cortex slices from control and chronic NMDA administered rats. Magnification is at 40 × objective. FJB positive neurons were only observed in the brains of chronic NMDA administered rats. [27], induced mitochondrial damage [25], activated caspases-3 and -9, released cytochrome C from mitochondria [26] and decreased neuronal viability [28].

BDNF protein in spinal cord neurons in vitro
Expression of BDNF and Bcl-2 is regulated mainly by CREB [42]. BDNF and Bcl-2 play important roles in cell survival and plasticity, and in growth and differentiation of new neurons and synapses [43]. Increased AA signaling may interfere with transcription of neuronal survival factors [27,[44][45][46][47]. Downregulation of BDNF and Bcl-2 could occur through a decrease in their transcription factor phospho-CREB [48], as was found in this study. BDNF also may regulate Bcl-2 levels through activation of the MAP kinase cascade and the downstream phosphorylation of CREB protein [49].
Bcl-2 can be repressed by the AP-2 transcription factor [50], resulting in apoptosis. Chronic NMDA in rats increased the DNA-binding activity of AP-2 and protein levels of its alpha and beta subunits [51]. AP-2 also is a transcription factor of the cPLA 2 gene, and its overexpression may lead to upregulated cPLA 2 activity and of AA signaling upon chronic NMDA administration [51]. Thus, increased AP-2 binding activity or decreased BDNF caused by chronic NMDA may have led to the decreased Bcl-2 expression in the present study.
Consistent with the notion that increased AA signaling reduces BDNF expression, rats deprived of dietary essential n-3 PUFAs for 15 weeks demonstrated increased brain AA signaling and reduced mRNA and protein levels of phospho-CREB and BDNF [29,30]. In relation to this, chronic NMDA administration also increased brain cPLA 2 activity, phosphorylation, protein, and mRNA levels, as well as AA turnover in brain phospholipids [6,35].
14-3-3ζ proteins bind the pro-apoptotic protein Bad [52]. Disassociation of 14-3-3ζ from Bad causes dephosphorylation of Bad by protein phosphatase 2A [53], allowing Bad to move from the cytoplasm to mitochondria, where it can displace Bax from Bcl-xL [54] and promote apoptosis. There also may be a more direct mechanism by which AA induces polymerization of 14-3-3ζ and dissociation from Bad [55]. The combination of increased expression of 14-3-3ζ and increased AA signaling [6] caused by chronic NMDA may have contributed to the neuronal loss, which is suggested by the increased FJB staining. Studies also have reported increased protein levels of 14-3-3ζ associated with neurodegenerative disease [56][57][58]. Increased 14-3-3ζ protein levels caused by chronic NMDA may be a secondary response to the observed increased Bad expression or be due to the increased AA signalling. Further studies are needed to understand the direct role of 14-3-3ζ in NMDA mediated apoptosis.

Conclusion
Chronic NMDA excitotoxicity may be involved in the apoptosis in neurodegenerative diseases, while targeting the excitotoxicity with drugs may be a useful therapeutic approach in these neurodegenerative diseases by way of reducing apoptosis in brain.